Atlas Trials

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Clinical trial NCT02289222 · TERMINATED

Trial details

NCT number
NCT02289222
Sponsor
Ashraf Badros
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2014-12-30
Primary completion
2017-08-07
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.